Bringing the fundamentals into focus…
Back to Vor Biopharma Inc.
How Vor Biopharma Inc. stacks up
VOR · against 469 other Healthcare companies of similar size
Valuation
75/ 100
Above the middle of the pack.
Ranked #137 of 470 · scores higher than 70% of peers
Bars: peers in each 10-point band of the valuation score50 peers with a valuation score of 70–79, including VOR · Click a bar to see the companies
Why valuation scores 75?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield, which is stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -16.5% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -12.0% vs peer median 0.0%
- higher earnings for the price paid: stronger than 100% of peers. Earnings yield: 909.3% vs peer median 1.5%
Metric by metric
Position: dot = VOR, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | VOR | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 461 reported | 909.3% | 1.4% | 100% | 30% | |
| EBITDA yieldHigher is better · 473 reported | -16.5% | 4.3% | 10% | 50% | |
| Free cash flow yieldHigher is better · 206 reported | -12.0% | -1.6% | 19% | 20% | |
| Book yieldHigher is better · 465 reported | -18.5% | 40.8% | 1% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around VORScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score